Shigeru Furuta
Central Research Laboratories
Zeria Pharmaceutical Co.
Ltd., 2512-1 Oshikiri
Konan-machi
Japan
Name/email consistency: high
- Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338. Furuta, S., Kamada, E., Omata, T., Sugimoto, T., Kawabata, Y., Yonezawa, K., Wu, X.C., Kurimoto, T. Eur. J. Pharmacol. (2004)
- Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential. Furuta, S., Akagawa, N., Kamada, E., Hiyama, A., Kawabata, Y., Kowata, N., Inaba, A., Matthews, A., Hall, M., Kurimoto, T. Br. J. Clin. Pharmacol (2002)
- Pharmacodynamic analysis of steroid 5alpha-reductase inhibitory actions of Z-350 in rat prostate. Furuta, S., Fukuda, Y., Sugimoto, T., Miyahara, H., Kamada, E., Sano, H., Fukuta, Y., Takei, M., Kurimoto, T. Eur. J. Pharmacol. (2001)